Previous 10 | Next 10 |
Summary IGALMI's second full launch quarter is underway; expect modest revenues and increasing expenses for the balance of 2023. IGALMI's label supervision, and its approval letter postmarketing requirements, both merit investor consideration. BioXcel's strong late-stage pipeline sh...
BioXcel Therapeutics ( NASDAQ: BTAI ) said its oral medicine BXCL701 in combination with Merck's ( NYSE: MRK ) Keytruda showed encouraging response rate in patients with a type of prostate cancer in a phase 2a trial. The study evaluated BXCL701 in combinatio...
Results demonstrate encouraging response rate of BXCL701 plus KEYTRUDA ® (pembrolizumab) in patients with SCNC Full data will be presented at the 2023 ASCO Genitourinary Cancers Symposium in February NEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- BioXcel Ther...
NEW HAVEN, Conn., Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel ...
Pivotal trial will evaluate efficacy and safety of BXCL501 in Alzheimer’s patients in nursing homes with moderate to severe dementia Estimated 100 million annual Alzheimer’s-related agitation episodes 1 could potentially increase current U.S. market opportunity...
Shares of BioXCel Therapeutics (NASDAQ: BTAI) rose by as much as 19.1% this week, and as of Thursday afternoon, were still up 17% for the week, according to data from S&P Global Intelligence . The biotech stock closed last Friday at $17.02 a share and opened Monday at $17.15. Its ...
Some biotech stocks are positioned to deliver outsized returns in a short period, but those that do generally come with a healthy amount of risk. Consider, for instance, Editas Medicine (NASDAQ: EDIT) and BioXcel Therapeutics (NASDAQ: BTAI) . These two small-cap biotechs are l...
Investors were good to BioXcel Therapeutics (NASDAQ: BTAI) stock this week, particularly after a top-shelf investment bank upgraded its recommendation on the shares. All told, in the Monday to Friday trading period, the company's stock price rose by more than 16%, according to data compil...
NEW HAVEN, Conn., Dec. 01, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chi...
SERENITY III will evaluate the efficacy and safety of BXCL501 for at-home use Top-line pivotal data expected in 1H 2023 Estimated 23 million annual agitation episodes in the home-setting would more than double current market opportunity for BXCL501 in the U.S. 1 -4...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...